Grimprel E - Search Results

1

Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: a review.

Jacquet JM, Bégué P, Grimprel E, Reinert P, Sandbu S, Silfverdal SA, Faldella G, Nolan T, Lambert S, Richmond P, Marshall H, Roberton D, Schuerman L. Jacquet JM, et al. Among authors: grimprel e. Vaccine. 2006 Mar 20;24(13):2440-8. doi: 10.1016/j.vaccine.2005.12.009. Epub 2005 Dec 20. Vaccine. 2006. PMID: 16406224 Clinical Trial.

2

Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.

Grimprel E, von Sonnenburg F, Sänger R, Abitbol V, Wolter JM, Schuerman LM. Grimprel E, et al. Vaccine. 2005 May 25;23(28):3657-67. doi: 10.1016/j.vaccine.2005.02.013. Vaccine. 2005. PMID: 15882526 Clinical Trial.

3

Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix(®)) in adults 55 years of age and over: a sub-analysis of four trials.

Van Damme P, McIntyre P, Grimprel E, Kuriyakose S, Jacquet JM, Hardt K, Messier M, Van Der Meeren O. Van Damme P, et al. Among authors: grimprel e. Vaccine. 2011 Aug 11;29(35):5932-9. doi: 10.1016/j.vaccine.2011.06.049. Epub 2011 Jun 28. Vaccine. 2011. PMID: 21718738 Clinical Trial.

4

Comparative reactogenicity and immunogenicity of booster doses of diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine and diphtheria-tetanus-inactivated poliovirus vaccine in preadolescents.

Bégué PC, Grimprel EM, Giovannangeli MD, Abitbol VI. Bégué PC, et al. Among authors: grimprel em. Pediatr Infect Dis J. 1998 Sep;17(9):804-9. doi: 10.1097/00006454-199809000-00011. Pediatr Infect Dis J. 1998. PMID: 9779766 Clinical Trial.

5

Future combined vaccines.

Bégué P, Grimprel E. Bégué P, et al. Among authors: grimprel e. J Infect Dis. 1996 Nov;174 Suppl 3:S295-7. doi: 10.1093/infdis/174.supplement_3.s295. J Infect Dis. 1996. PMID: 8896533

6

[What uses for the acellular pertussis vaccine?].

Grimprel E, Bégué P. Grimprel E, et al. Arch Pediatr. 1998 May;5(5):557-60. doi: 10.1016/s0929-693x(99)80323-6. Arch Pediatr. 1998. PMID: 9759192 French.

7

Pertussis: the new acellular vaccines.

Grimprel E, Bégué P. Grimprel E, et al. Pediatr Pulmonol Suppl. 1995;11:84-5. doi: 10.1002/ppul.1950191142. Pediatr Pulmonol Suppl. 1995. PMID: 7547361 No abstract available.

8

Immunogenicity and safety of fully liquid DTaP₅-IPV-Hib compared with DTaP₃-IPV/Hib when both coadministered with a heptavalent pneumococcal conjugate vaccine (PCV7) at 2, 3, 4, and 12 to 18 months of age: a phase III, single-blind, randomised, controlled, multicentre study.

Grimprel E, Wysocki J, Boisnard F, Thomas S, Mwawasi G, Reynolds D. Grimprel E, et al. Vaccine. 2011 Oct 6;29(43):7370-8. doi: 10.1016/j.vaccine.2011.07.078. Epub 2011 Jul 30. Vaccine. 2011. PMID: 21807056 Clinical Trial.

9

Influence of vaccination coverage on pertussis transmission in France.

Grimprel E, Baron S, Lévy-Bruhl D, Garnier JM, N'jamkepo E, Guiso N, Bégué P. Grimprel E, et al. Lancet. 1999 Nov 13;354(9191):1699-700. doi: 10.1016/S0140-6736(99)01576-7. Lancet. 1999. PMID: 10568576

10

[Epidemiology of pertussis in industrialized countries].

Baron S, Bégué P, Grimprel E. Baron S, et al. Among authors: grimprel e. Sante. 1994 May-Jun;4(3):195-200. Sante. 1994. PMID: 7921686 Free article. French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

157 results

Search Page

Filters